Moving from Exploratory Collaborations to Record-Setting Deals in IO

In early March, we wrote about the collaboration between Bristol-Myers Squibb and Nektar aimed at developing Nektar’s T-cell stimulating molecule NKTR-214 in combination with BMS’s checkpoint inhibitor Opdivo (nivolumab). That deal brought Nektar an eye-opening $1.85 billion in upfront cash… Read »

Apps and Drugs/ Apps as Drugs

In our January post on what we planned to watch for in 2018, we predicted that digital health would come to the foreground of activity this year. And indeed, we are starting to see a lot of buzz around digital… Read »

The Rise of AI in Drug Discovery and Development

“Deep learning” is an advanced machine learning technology that enables the generation of relevant insights from enormous amounts of data. Computers are able to identify complex patterns in data from many disparate sources and generate algorithms to explain them. This… Read »

Chasing Migraine

Migraine is the most prevalent neurological disorder worldwide. It causes not only painful headaches, but can also be associated with nausea, vomiting, light and noise sensitivity, and fatigue. A migraine attack can last from a few hours to several days…. Read »

Artificial Intelligence Making Gains in Health Care

Applications of artificial intelligence (AI) to health care took a major step forward with two noteworthy events in February in the cardiovascular space.   In the first case, the U.S. Food and Drug Administration (FDA) approved the marketing of a… Read »

Alzheimer’s Disease: Continued Clinical Failure and a Potential New Development Pathway

Alzheimer’s disease continues to be a costly and frustrating minefield for drug developers. Most recently, Boehringer Ingelheim halted development of the phosphodiesterase type 9 (PDE9) inhibitor BI 409306 after it failed in phase 2. Merck also ended its trial of verubecestat,… Read »

Setting (Financial) Records in I/O

 On February 14, Bristol-Myers Squibb (BMS) and Nektar announced the largest-ever deal in history involving a single development-stage drug in a partnership that greatly expands combination testing of BMS’s checkpoint inhibitor Opdivo (nivolumab) and Nektar’s T-cell stimulating molecule NKTR-214.  … Read »

Merger Mania

Back in January, one of our predictions for the year included a ramp up in M&A activities on all fronts, driven in part by corporate tax reductions that left many companies with plenty of cash for acquisitions. While news during… Read »

Reinventing Medical Affairs to the Benefit of All

The concept of patient-centric drug development has been a frequent topic of discussion in recent years. Increasingly, companies have moved to adopt practices that create more active, networked relationships and interactions between physicians, patients, advocates and drug developers. The aim… Read »

Enter the Giants: Amazon, Berkshire Hathaway and J.P. Morgan Take on Healthcare

Recent months have seen a series of corporate actions aimed at reconfiguring healthcare in the United States, beginning with drug store giant CVS’s bid in December 2017 to purchase Aetna, one of the country’s biggest insurers, for about $69 billion…. Read »

1 2 3 9